MedTech startup announces TGA approval of AI-powered imaging analysis technology

Digital & Innovation: See-Mode Technologies, a MedTech startup based in Australia and Singapore empowering clinicians to better predict stroke, has received regulatory approvals from the Therapeutic Goods Administration (TGA) and CE Mark, for the Augmented Vascular Analysis (AVA) software.

AVA uses Artificial Intelligence (AI) to perform automated analysis and reporting of vascular ultrasound, CT or MRI scans, enabling clinicians to interpret and report on these scans more efficiently and with higher quality.

Despite the importance of ultrasound studies for diagnosis and treatment of patients with vascular conditions, analysis and reporting of these scans are primarily done manually, using pen and paper.

Through its use of deep learning, text recognition, and signal processing, AVA improves the speed and quality of the process significantly. With a single click and in less than a minute, AVA can analyse a full vascular ultrasound scan, minimising the need for manual drawings. This helps to augment the clinical workflow, resulting in greater overall productivity, accuracy, and improved patient outcome.

“Since See-Mode’s inception, we have seen that clinicians are increasingly looking for ways to speed up their workflow while improving patient care. Thus, we are proud that AVA has obtained CE Mark and TGA approval – on top of the earlier clearances from FDA and HSA – to help with analysis and reporting of vascular studies,” said Dr Sadaf Monajemi, Co-Founder and Director, See-Mode Technologies.

“Achieving four regulatory approvals as a three-year-old startup was no easy feat. This clearly demonstrates the scientific rigour with which we have built and validated our product and we are extremely thankful to have the support of our clinical partners. Having reached this significant milestone for See-Mode, we look forward to continuing our commercial growth trajectory in Europe and Australia.”

See-Mode has embarked on research partnerships with healthcare institutions such as Austin Health and Royal Melbourne Hospital in Australia and the National University Hospital and Changi General Hospital in Singapore, for further validation of its algorithms and models to assist clinicians in image interpretation and stroke prediction.

See-Mode is continuously adding more image interpretation and reporting capabilities to AVA and expanding the product’s capabilities to new clinical use cases. Continuing on its mission to assist doctors in predicting and preventing stroke, See-Mode is currently running clinical validation studies for its future algorithms on the detection of high risk plaques and high risk blood flow with partners across Australia, Singapore, Europe and the United States.

See-Mode aims to rapidly scale its business across its core markets, namely Australia, Europe, the United States and Singapore.